RecruitingNot ApplicableNCT05898594

Lung Cancer Screening in High-risk Black Individuals

Evaluating the Feasibility of Lung Cancer Screening in High-risk Black Individuals


Sponsor

Massachusetts General Hospital

Enrollment

900 participants

Start Date

Sep 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this research study is to study U.S. Black individuals with a history of smoking to examine the feasibility, acceptability, and performance of low-dose computed tomography (LDCT) screening among this population. The name of the intervention used in this research study is: Low-dose computed tomography (radiologic scan) chest scan


Eligibility

Min Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is offering free lung cancer screening through low-dose CT scans to Black individuals who smoke or have a history of smoking, a group often underrepresented in standard screening programs. **You may be eligible if...** - You self-identify as Black - You are between 50 and 80 years old - You have a history of smoking (any amount) **You may NOT be eligible if...** - You have a history of lung cancer - You currently have symptoms that could suggest lung cancer (unexplained persistent cough, shortness of breath, easily winded) - You had pneumonia or an acute respiratory infection in the past 12 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELow-dose Computed Tomography

Per standard care


Locations(2)

University of Chicago

Chicago, Illinois, United States

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05898594


Related Trials